Synapse Open Synapse
Biology

The cost of waiting: what licensing a biotech asset early really saves you

Labiotech.eu ·

In recent years, biopharma has paid significantly different prices for the same underlying technology. In March 2025, AstraZeneca agreed to pay EsoBiotec, an in vivo CAR-T platform with early single-patient data, $425 million upfront and up to $575 million more in milestones.

Latest from Labiotech.eu